DK1713813T3 - Polymorfe former af en gabaa agonist - Google Patents
Polymorfe former af en gabaa agonistInfo
- Publication number
- DK1713813T3 DK1713813T3 DK05702040T DK05702040T DK1713813T3 DK 1713813 T3 DK1713813 T3 DK 1713813T3 DK 05702040 T DK05702040 T DK 05702040T DK 05702040 T DK05702040 T DK 05702040T DK 1713813 T3 DK1713813 T3 DK 1713813T3
- Authority
- DK
- Denmark
- Prior art keywords
- polymorphic forms
- gabaa agonist
- gabaa
- agonist
- polymorphic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402118.4A GB0402118D0 (en) | 2004-01-30 | 2004-01-30 | Polymorphic forms of a GABAA agonist |
| PCT/GB2005/000288 WO2005073237A2 (en) | 2004-01-30 | 2005-01-28 | Polymorphic forms of a gabaa agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1713813T3 true DK1713813T3 (da) | 2009-02-16 |
Family
ID=31971783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05702040T DK1713813T3 (da) | 2004-01-30 | 2005-01-28 | Polymorfe former af en gabaa agonist |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7262300B2 (da) |
| EP (2) | EP1713813B1 (da) |
| JP (1) | JP4917440B2 (da) |
| KR (1) | KR101210361B1 (da) |
| CN (1) | CN1914212B (da) |
| AR (1) | AR047511A1 (da) |
| AT (1) | ATE414088T1 (da) |
| AU (1) | AU2005209473B2 (da) |
| BR (1) | BRPI0506858A (da) |
| CA (1) | CA2554536C (da) |
| CO (1) | CO5700743A2 (da) |
| CY (1) | CY1108647T1 (da) |
| DE (1) | DE602005010975D1 (da) |
| DK (1) | DK1713813T3 (da) |
| DO (1) | DOP2005000013A (da) |
| EA (1) | EA009413B1 (da) |
| EC (1) | ECSP066735A (da) |
| ES (1) | ES2314613T3 (da) |
| GB (2) | GB0402118D0 (da) |
| HK (1) | HK1096547A1 (da) |
| HR (1) | HRP20080614T3 (da) |
| IL (1) | IL176863A0 (da) |
| MA (1) | MA28364A1 (da) |
| MX (1) | MXPA06008595A (da) |
| MY (1) | MY139525A (da) |
| NO (1) | NO20063843L (da) |
| NZ (1) | NZ548191A (da) |
| PE (1) | PE20050769A1 (da) |
| PL (1) | PL1713813T3 (da) |
| PT (1) | PT1713813E (da) |
| SI (1) | SI1713813T1 (da) |
| TW (1) | TWI345972B (da) |
| UA (1) | UA87487C2 (da) |
| WO (1) | WO2005073237A2 (da) |
| ZA (1) | ZA200605307B (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
| NZ566062A (en) | 2005-09-28 | 2009-08-28 | Auris Medical Ag | Pharmaceutical compositions for the treatment of inner ear disorders comprising an arylcycloalkylamine such as ketamine and a biocompatible polymer |
| CN102093387B (zh) * | 2009-12-10 | 2012-07-25 | 天津泰普医药知识产权流转储备中心有限公司 | 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物 |
| ES2862673T3 (es) | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
| IL305342A (en) * | 2015-07-17 | 2023-10-01 | Ovid Therapeutics Inc | Methods for treating developmental disorders with gaboxadol |
| AU2017311412B2 (en) | 2016-08-11 | 2023-05-18 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
| EP3528807A4 (en) * | 2016-11-22 | 2020-06-17 | Ovid Therapeutics Inc | METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| US10813918B2 (en) | 2017-08-04 | 2020-10-27 | Ovid Therapeutics Inc. | Use of Gaboxadol in the treatment of diabetes and related conditions |
| JP2022501384A (ja) | 2018-09-20 | 2022-01-06 | オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. | トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用 |
| WO2020106927A1 (en) | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| CA3123876A1 (en) | 2018-12-17 | 2020-06-25 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| JP2023507764A (ja) | 2019-12-18 | 2023-02-27 | オービッド・セラピューティクス・インコーポレイテッド | １ｐ３６欠失症候群の治療的処置のためのガボキサドール |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | A canceled gaboxadol ring and its use for the treatment of psychiatric disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) * | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4315934A (en) * | 1979-09-24 | 1982-02-16 | Sandoz Ltd. | Organic compounds |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4352731A (en) * | 1980-11-03 | 1982-10-05 | Occidental Research Corporation | Apparatus for selective wetting of particles |
| DE19525598C2 (de) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| UA52661C2 (uk) * | 1996-06-14 | 2003-01-15 | Ново Нордіск А/С | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти |
| AU7405000A (en) | 1999-09-28 | 2001-04-30 | H. Lundbeck A/S | Melt granulated composition and modified release dosage form prepared from said composition |
| AR031473A1 (es) | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| ES2257559T3 (es) | 2001-05-18 | 2006-08-01 | Lonza Ag | Procedimiento para la preparacion de formulaciones solidas de 3-hidroxi-3-metilbutirato de sodio. |
| AR033896A1 (es) | 2001-05-21 | 2004-01-07 | Lundbeck & Co As H | Preparaciones granuladas de gaboxadol. |
| CN100491366C (zh) * | 2002-09-03 | 2009-05-27 | 华晶基因技术有限公司 | 汉黄芩素用作治疗焦虑症的药物的用途 |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| WO2004112786A2 (en) * | 2003-06-25 | 2004-12-29 | H. Lundbeck A/S | Gaboxadol for treating depression and other affective disorders |
| AR045540A1 (es) | 2003-09-05 | 2005-11-02 | Lundbeck & Co As H | Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip) |
| WO2005023256A1 (en) | 2003-09-10 | 2005-03-17 | Merck Sharp & Dohme Limited | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| TW200528098A (en) | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| EP1761263A1 (en) | 2004-06-29 | 2007-03-14 | H. Lundbeck A/S | Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis |
| GB0417558D0 (en) | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | POLYMORPHIC FORMS OF A GABAA AGONIST |
| WO2006102093A1 (en) | 2005-03-18 | 2006-09-28 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| EP1906953A4 (en) | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
-
2004
- 2004-01-30 GB GBGB0402118.4A patent/GB0402118D0/en not_active Ceased
-
2005
- 2005-01-20 AR ARP050100210A patent/AR047511A1/es not_active Application Discontinuation
- 2005-01-21 TW TW094101857A patent/TWI345972B/zh not_active IP Right Cessation
- 2005-01-24 MY MYPI20050253A patent/MY139525A/en unknown
- 2005-01-27 PE PE2005000102A patent/PE20050769A1/es not_active Application Discontinuation
- 2005-01-28 DE DE602005010975T patent/DE602005010975D1/de active Active
- 2005-01-28 AT AT05702040T patent/ATE414088T1/de active
- 2005-01-28 SI SI200530521T patent/SI1713813T1/sl unknown
- 2005-01-28 EA EA200601404A patent/EA009413B1/ru not_active IP Right Cessation
- 2005-01-28 CN CN2005800031615A patent/CN1914212B/zh active Active
- 2005-01-28 BR BRPI0506858-4A patent/BRPI0506858A/pt not_active IP Right Cessation
- 2005-01-28 DO DO2005000013A patent/DOP2005000013A/es unknown
- 2005-01-28 GB GB0501847A patent/GB2410434A/en not_active Withdrawn
- 2005-01-28 MX MXPA06008595A patent/MXPA06008595A/es active IP Right Grant
- 2005-01-28 PT PT05702040T patent/PT1713813E/pt unknown
- 2005-01-28 UA UAA200609410A patent/UA87487C2/ru unknown
- 2005-01-28 ES ES05702040T patent/ES2314613T3/es active Active
- 2005-01-28 AU AU2005209473A patent/AU2005209473B2/en not_active Ceased
- 2005-01-28 NZ NZ548191A patent/NZ548191A/en not_active IP Right Cessation
- 2005-01-28 DK DK05702040T patent/DK1713813T3/da active
- 2005-01-28 WO PCT/GB2005/000288 patent/WO2005073237A2/en active Search and Examination
- 2005-01-28 EP EP05702040A patent/EP1713813B1/en active Active
- 2005-01-28 US US11/045,768 patent/US7262300B2/en active Active
- 2005-01-28 PL PL05702040T patent/PL1713813T3/pl unknown
- 2005-01-28 JP JP2006550301A patent/JP4917440B2/ja active Active
- 2005-01-28 CA CA2554536A patent/CA2554536C/en not_active Expired - Fee Related
- 2005-01-28 EP EP08019457A patent/EP2042505A1/en not_active Withdrawn
-
2006
- 2006-06-27 ZA ZA200605307A patent/ZA200605307B/en unknown
- 2006-07-13 IL IL176863A patent/IL176863A0/en unknown
- 2006-07-26 CO CO06073254A patent/CO5700743A2/es not_active Application Discontinuation
- 2006-07-28 EC EC2006006735A patent/ECSP066735A/es unknown
- 2006-07-28 KR KR1020067015417A patent/KR101210361B1/ko not_active IP Right Cessation
- 2006-08-22 MA MA29278A patent/MA28364A1/fr unknown
- 2006-08-29 NO NO20063843A patent/NO20063843L/no not_active Application Discontinuation
-
2007
- 2007-02-23 HK HK07102068A patent/HK1096547A1/xx unknown
- 2007-07-13 US US11/827,570 patent/US8236958B2/en active Active
-
2008
- 2008-11-26 HR HR20080614T patent/HRP20080614T3/xx unknown
- 2008-12-10 CY CY20081101439T patent/CY1108647T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1713813T3 (da) | Polymorfe former af en gabaa agonist | |
| DK2064189T3 (da) | Polymorfe former af 4-[3-(4-cyklopropancarbonyl-piperazin-1-carbonyl)-4-fluor-benzyl]-2H-phathalazin-1-on | |
| DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
| DK1856050T3 (da) | Krystallinske former af en biphenylforbindelse | |
| DK1778618T3 (da) | Syntese af triethylentetraminer | |
| DK1778672T3 (da) | Krystallinsk form af en biphenylforbindelse | |
| BRPI0806945A2 (pt) | Formas polimórficas de um inibidor macrocíclico de hcv | |
| DK2371818T3 (da) | Hydroxybenzoatsalte af metanikotinforbindelser | |
| DK1963302T3 (da) | Polymorfer af en C-MET/HGFR-inhibitor | |
| DK1737461T3 (da) | Carbolin-derivater til inhibering af angiogenese | |
| DK2117542T3 (da) | Kombinationer af beta-2-adrenoceptor-agonistisk benzothiazolon | |
| DK2489662T3 (da) | Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater | |
| DK1917253T3 (da) | Fremgangsmåde til fremstilling af betamimetika | |
| DK2127449T3 (da) | Tidsplanlægning af en dynamisk radiokanal | |
| DK2402005T3 (da) | Formuleringer med langvarig frigivelse af nalbuphin | |
| DK2073636T3 (da) | Fremgangsmåde til fremstilling af oxymorphon | |
| DK2126801T3 (da) | Fremgangsmåde til udvælgelse af information | |
| DK2111555T3 (da) | Diagnosticering af præeklampsi | |
| DK2021309T3 (da) | Fremgangsmåde til fremstilling af methanol | |
| DK2083629T3 (da) | Krystallinsk modifikation af fipronil | |
| DK2235046T3 (da) | Mutante former af streptolysin-O | |
| DK2019118T3 (da) | Fremgangsmåde til syntetisering af thymosiner | |
| DK2228656T3 (da) | Kvantificering af allergener | |
| DK1825484T3 (da) | Fremgangsmåde til fremstilling af kabler | |
| DK1794111T3 (da) | Fremgangsmåde til fremstilling af cyclopentanon |